Abstract
Background: Physostigmine, commonly used as an antidote in anticholinergic poisoning, is reported to have additional pharmacological effects, such as activation of the cholinergic anti-inflammatory pathway in sepsis models. Due to the narrow therapeutic range of physostigmine and its metabolite eseroline, however, the plasma concentrations of these substances need to be determined so as to understand their effect and ensure safety in the treatment of septic patients.
Methods: To determine physostigmine and its metabolite eseroline, a rapid and sensitive high performance liquid chromatography (HPLC) method has been developed and validated. Spiked plasma samples were cleaned up and concentrated using a simple liquid-liquid extraction (LLE) procedure with N-methylphysostigmine as internal standard. Separation was achieved using reversed-phase HPLC on a Kinetex C18 column with gradient elution and fluorescence detection (254 nm excitation/355 nm emission).
Results: LLE produced clean extracts and a mean recovery of 80.3% for eseroline and 84.9% for physostigmine. The HPLC assay revealed a limit of detection (LOD) of 0.025 ng/mL and a lower limit of quantification (LLOQ) of 0.05 ng/mL for both analytes. Linearity was observed at 0.05–10.0 ng/mL (r2>0.999). Intra- and inter-day precision ranged from 0.7% to 6.6%, and intra- and inter-day accuracy 97.5%–110.0%.
Conclusions: The presented method is useful for human drug level monitoring of physostigmine and eseroline in accordance with current guidelines. Remarkably low plasma concentrations can be quantified after LLE with gradient elution and fluorescence detection, making this a suitable method for pharmacokinetic studies in a clinical setting.
Acknowledgments
The authors would like to thank Dr. Jürgen Burhenne, Heidelberg, and Prof. Frieder Kees, Regensburg, for kindly sharing their expertise in HPLC and liquid-liquid extraction procedures.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Financial support: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Triggle DJ, Mitchell JM, Filler R. The pharmacology of physostigmine. CNS Drug Rev 1998;4:87–136.10.1111/j.1527-3458.1998.tb00059.xSearch in Google Scholar
2. Somani SM, Dube SN. Physostigmine – an overview as pretreatment drug for organophosphate intoxication. Int J Clin Pharmacol Ther Toxicol 1989;27:367–87.Search in Google Scholar
3. Zhao B, Moochhala SM, Tham SY. Biologically active components of Physostigma venenosum. J Chromatogr B Analyt Technol Biomed Life Sci 2004;812:183–92.10.1016/S1570-0232(04)00677-4Search in Google Scholar
4. Asthana S, Greig NH, Hegedus L, Holloway HH, Raffaele KC, Schapiro MB, et al. Clinical pharmacokinetics of physostigmine in patients with Alzheimer’s disease. Clin Pharmacol Ther 1995;58:299–309.10.1016/0009-9236(95)90246-5Search in Google Scholar
5. Furey ML, Pietrini P, Alexander GE, Mentis MJ, Szczepanik J, Shetty U, et al. Time course of pharmacodynamic and pharmacokinetic effects of physostigmine assessed by functional brain imaging in humans. Pharm Biochem Behav 2000;66:475–81.10.1016/S0091-3057(00)00186-6Search in Google Scholar
6. ISRCTN registry. Peri-operative physostigmine prophylaxis for liver resection patients at risk for delirium and post-operative cognitive dysfunction. ISRCTN18978802. Available at: http://www.isrctn.com/ISRCTN18978802. Accessed on December 10, 2014.Search in Google Scholar
7. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405:458–62.10.1038/35013070Search in Google Scholar
8. Hofer S, Eisenbach C, Lukic IK, Schneider L, Bode K, Brueckmann M, et al. Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med 2008;36:404–8.10.1097/01.CCM.0B013E31816208B3Search in Google Scholar
9. Bartolini A, Di Cesare Mannelli L, Ghelardini C. Analgesic and antineuropathic drugs acting through central cholinergic mechanisms. Recent Pat CNS Drug Discov 2011;6:119–40.10.2174/157488911795933901Search in Google Scholar
10. Somani SM, Kutty RK, Krishna G. Eseroline, a metabolite of physostigmine, induces neuronal cell death. Toxicol Appl Pharmacol 1990;106:28–37.10.1016/0041-008X(90)90102-ZSearch in Google Scholar
11. Whelpton R, Moore T. Sensitive liquid chromatographic method for physostigmine in biological fluids using dual-electrode electrochemical detection. J Chromatogr 1985;341:361–71.10.1016/S0378-4347(00)84049-9Search in Google Scholar
12. Azevedo Marques L, Giera M, Lingeman H, Niessen WM. Analysis of acetylcholinesterase inhibitors: bioanalysis, degradation and metabolism. Biomed Chromatogr 2011;25:278–99.10.1002/bmc.1573Search in Google Scholar PubMed
13. Lawrence GD, Yatim N. Extraction of physostigmine from biologic fluids and analysis by liquid chromatography with electrochemical detection. J Pharmacol Methods 1990;24: 137–43.10.1016/0160-5402(90)90024-FSearch in Google Scholar
14. Wu YQ, Reinecke E. High performance liquid chromatographic method for detection of physostigmine and eseroline in plasma using a silica gel column and a perchloric acid mobile phase. J Liq Chromatogr 1990;13:275–90.10.1080/01483919008049543Search in Google Scholar
15. Zhao B, Moochhala SM, Chaw CS, Yang YY. Simple liquid chromatographic method for the determination of physostigmine and its metabolite eseroline in rat plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2003;784:323–9.10.1016/S1570-0232(02)00817-6Search in Google Scholar
16. FDA – U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for Industry – Bioanalytical Method Validation. 2001.Search in Google Scholar
17. Rubnov S, Levy D, Schneider H. Liquid chromatographic analysis of physostigmine salicylate and its degradation products. J Pharmaceut Biomed Anal 1999;18:939–45.10.1016/S0731-7085(98)00099-5Search in Google Scholar
18. Walter K, Muller M, Barkworth MF, Nieciecki AV, Stanislaus F. Pharmacokinetics of physostigmine in man following a single application of a transdermal system. Br J Clin Pharmacol 1995;39:59–63.10.1111/j.1365-2125.1995.tb04410.xSearch in Google Scholar
19. Brodie RR, Chasseaud LF, Robbins AD. Determination of physostigmine in plasma by high-performance liquid chromatography. J Chromatogr 1987;415:423–31.10.1016/S0378-4347(00)83238-7Search in Google Scholar
©2015 by De Gruyter
